Incyte (INCY) Stock Dips Despite Japan’s Green Light for Minjuvi in DLBCL Treatment

Incyte (INCY) stock dropped 0.78% to $98.22 as Japan approved Minjuvi for relapsed DLBCL treatment, marking the drug's second approval in the country.

The post Incyte (INCY) Stock Dips Despite Japan’s Green Light for Minjuvi in DLBCL Treatment appeared first on Blockonomi.